Market Overview

Mycosis Fungoides | A Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the mycosis
fungoides market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat mycosis fungoides.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180723005555/en/

Technavio has published a new report on the drug development pipeline for mycosis fungoides, includi ...

Technavio has published a new report on the drug development pipeline for mycosis fungoides, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Mycosis fungoides: Market overview

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma
constituting over 70% of CTCL. It mostly affects the skin and progresses
internally over time. The disease progresses through various stages but
not all patients with mycosis fungoides go through all stages. The final
stage of mycosis fungoides is known as Sezary syndrome. If left
untreated, mycosis fungoides may spread to other parts of the body such
as gastrointestinal system, liver, spleen, or brain. The most common age
group affected by mycosis fungoides is 40 years and above. The pattern
of inheritance of mycosis fungoides is not determined. Though there have
been various cases where multiple members of a family were affected with
mycosis fungoides, it most often occurs in people with no history of the
disorder in the family.

According to a senior market research analyst at Technavio, "On the
gender front, mycosis fungoides is more common in men than in women.
According to the National Institutes of Health, the prevalence of
mycosis fungoides in men and women is in the ratio 2:1. The prevalence
of mycosis fungoides in the US is about 3.6 people per every 1,000,000
people. As a result, with rising incidences of the disease, the need for
drug development for mycosis fungoides is expected to increase
considerably in the forthcoming years."

Mycosis fungoides: Segmentation analysis

This pipeline analysis report segments the mycosis fungoides market
based on therapies employed (monotherapy, combination therapy and
monotherapy+combination therapy), RoA (intravenous, topical,
subcutaneous, oral, intravenous + oral, parenteral, and intratumoral),
therapeutic modality (small molecule, monoclonal antibody, recombinant
antibody, RNA and fusion protein), targets (PD1, HDAC6, and others), MoA
(PD1 inhibitor, and others), geographical segmentation (Americas, EMEA
and APAC) and recruitment status (active, not recruiting, completed, not
yet recruiting, and recruiting). It provides an in-depth analysis of the
prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, around 44% of the molecules that are
being investigated for the treatment of mycosis fungoides are small
molecule.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!